The FDA approved oral remibrutinib (Rhapsido) as a second-line treatment for chronic spontaneous urticaria (CSU), or chronic hives, Novartis announced on Tuesday. Indicated for adults with stubborn ...

The first oral BTK blocker for chronic spontaneous urticaria, Rhapsido offers a more convenient treatment option for patients who still show symptoms after antihistamine treatment.

Novartis AG won US approval for a new treatment for a hives-like skin condition, bolstering the Swiss drugmaker’s push into disorders of the immune system. Remibrutinib, which will be sold under the ...

Hot weather puts you into two entirely different moods. On one hand, it is a call for sun-soaked days, seaside vacations, or walk nights with a soothing breeze. On the contrary, for people like me who ...